» Articles » PMID: 8131275

Quantification of Lipoprotein(a) in Plasma by Assaying Cholesterol in Lectin-bound Plasma Fraction

Overview
Journal Clin Chem
Specialty Biochemistry
Date 1994 Mar 1
PMID 8131275
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Lipoprotein(a) [Lp(a)] is a low-density lipoprotein (LDL)-like particle in which apolipoprotein(a) [apo(a)] is disulfide-linked to apolipoprotein B (apoB). High concentrations of Lp(a) in plasma are associated with an increased risk of coronary heart disease (CHD). Lp(a) has traditionally been measured by immunoassay and expressed as total mass of Lp(a). Measuring Lp(a) by its cholesterol content will provide a way to directly compare Lp(a) with other lipoproteins that are measured by cholesterol. We have developed an assay to quantify Lp(a) by its cholesterol content [Lp(a)-C], using lectin affinity to isolate Lp(a) from other lipoproteins, and then measuring the cholesterol within the isolated fraction. We compared the Lp(a)-C assay with an ELISA for Lp(a) mass in 47 plasma samples from normotriglyceridemic, fasting individuals with high Lp(a) contents (mean +/- SD, 446 +/- 350 mg/L). The mean Lp(a)-C concentration was 110 +/- 89 mg/L and correlated very highly with Lp(a) mass (r = 0.9975). Lp(a)-C measurement is an alternative method to screen for this CHD risk factor.

Citing Articles

Assessing the Accuracy of Estimated Lipoprotein(a) Cholesterol and Lipoprotein(a)-Free Low-Density Lipoprotein Cholesterol.

Zheng W, Chilazi M, Park J, Sathiyakumar V, Donato L, Meeusen J J Am Heart Assoc. 2022; 11(2):e023136.

PMID: 35023348 PMC: 9238537. DOI: 10.1161/JAHA.121.023136.


Low-Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events.

Willeit P, Yeang C, Moriarty P, Tschiderer L, Varvel S, McConnell J J Am Heart Assoc. 2020; 9(23):e016318.

PMID: 33222611 PMC: 7763787. DOI: 10.1161/JAHA.119.016318.


Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans.

van der Valk F, Bekkering S, Kroon J, Yeang C, Van den Bossche J, van Buul J Circulation. 2016; 134(8):611-24.

PMID: 27496857 PMC: 4995139. DOI: 10.1161/CIRCULATIONAHA.116.020838.


Development of lipoprotein(a) siRNAs for mechanism of action studies in non-human primate models of atherosclerosis.

Tadin-Strapps M, Robinson M, Le Voci L, Andrews L, Yendluri S, Williams S J Cardiovasc Transl Res. 2015; 8(1):44-53.

PMID: 25604958 DOI: 10.1007/s12265-014-9605-1.


Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study.

Lamon-Fava S, Marcovina S, Albers J, Kennedy H, DeLuca C, White C J Lipid Res. 2011; 52(6):1181-1187.

PMID: 21478162 PMC: 3090239. DOI: 10.1194/jlr.M012526.